To determine whether AURKA may represent an appropriate therapeutic target in cholangiocarcinoma, we initially screened a panel of cholangiocarcinoma cell lines with Alisertib, a highly selective AURKA inhibitor. Here, AURKA is linked to cholangiocarcinoma.